Amgen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Amgen and other ETFs, options, and stocks.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
26,700
Employees26,700
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
26,700
Employees26,700

AMGN Key Statistics

Market cap
152.45B
Market cap152.45B
Price-Earnings ratio
37.89
Price-Earnings ratio37.89
Dividend yield
3.00%
Dividend yield3.00%
Average volume
3.21M
Average volume3.21M
High today
$292.48
High today$292.48
Low today
$279.62
Low today$279.62
Open price
$291.02
Open price$291.02
Volume
5.32M
Volume5.32M
52 Week high
$346.85
52 Week high$346.85
52 Week low
$260.52
52 Week low$260.52

AMGN News

TipRanks 1d
Wolfe Research starts Amgen at Peer Perform given approaching patent cliffs

Wolfe Research analyst Alexandria Hammond initiated coverage of Amgen (AMGN) with a Peer Perform rating. With the antibody backbone, the firm is acknowledges th...

TipRanks 1d
Amgen call volume above normal and directionally bullish

Bullish option flow detected in Amgen (AMGN) with 8,403 calls trading, 2x expected, and implied vol increasing over 3 points to 49.64%. Jan-25 295 calls and Jan...

Benzinga 2d
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density

On Tuesday, a Cantor analyst wrote that additional data from Amgen’s experimental weight loss injection, MariTide, suggests a new potential safety risk tied to...

Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density

Analyst ratings

51%

of 35 ratings
Buy
42.9%
Hold
51.4%
Sell
5.7%

More AMGN News

Investor's Business Daily 2d
Amgen Rebounds. But Do Eli Lilly And Viking Therapeutics Now Have The Upper Hand?

Amgen Rebounds. But Do Eli Lilly And Viking Therapeutics Now Have The Upper Hand?...

Amgen Rebounds. But Do Eli Lilly And Viking Therapeutics Now Have The Upper Hand?
Investor's Business Daily 3d
Amgen Rebounds, Shaking Off 'Overdone' Fears Tied To Its Weight-Loss Shot

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral density loss. View comments...

Amgen Rebounds, Shaking Off 'Overdone' Fears Tied To Its Weight-Loss Shot
Benzinga 3d
Jim Cramer Says Eli Lilly's 'Pathetic' Stock Performance Could Get A Breather If Amgen Has Hidden Bone Risk Data After 7% Stock Drop

Amgen Inc.‘s AMGN stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its experimental obesity drug MariTide, whil...

Jim Cramer Says Eli Lilly's 'Pathetic' Stock Performance Could Get A Breather If Amgen Has Hidden Bone Risk Data After 7% Stock Drop
CNBC 3d
Amgen stock falls as analysts mull over weight loss drug’s bone density data

Shares of Amgen fell more than 7% Tuesday as analysts chewed over bone density loss data from an early-stage trial on its experimental weight loss injection, Ma...

Amgen stock falls as analysts mull over weight loss drug’s bone density data
TipRanks 3d
Amgen’s AMG-133 Phase 1 bone data ‘seems non-issue,’ says Jefferies

Jefferies reviewed public data from the Phase 1 trial of AMG-133 showing additional measurements of bone density from obesity patients, which the firm says “cou...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.